Concise Prescribing Info
Susceptible infections.
Dosage/Direction for Use
Adult: PO 1-2 g/day as single or in 2 divided doses.
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Hypersensitivity to cefadroxil or to other cephalosporins.
Special Precautions
History of hypersensitivity to penicillins or any other β-lactam drugs. History of GI disease (particularly colitis), severe allergies or asthma. Renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause headache, dizziness, nervousness, sleeplessness and fatigue which may impair ability to drive or operate machinery. Monitoring Parameters Monitor renal function. Observe for signs and symptoms of anaphylaxis during 1st dose.
Adverse Reactions
Dyspepsia, nausea, vomiting, diarrhoea; allergies (e.g. rash, urticaria, angioedema, pruritus); hepatic dysfunction (e.g. cholestasis, elevated serum transaminase); genital pruritus, genital moniliasis, vaginitis, moderate transient neutropenia, fever. Rarely, agranulocytosis, thrombocytopenia, idiosyncratic hepatic failure, erythema multiforme, Stevens-Johnson syndrome, serum sickness, arthralgia.
Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
Drug Interactions
Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
CIMS Class
ATC Classification
J01DB05 - cefadroxil ; Belongs to the class of first-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on cefadroxil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in